Needham upgraded ICU Medical to Buy from Hold with a $165 price target. The firm expects the company to benefit from an IV system replacement cycle as well as challenges at peers. ICU's exposure to higher oil prices is limited, and management expects favorable tariff changes and efficiencies to offset the impact, the analyst tells investors in a research note. Needham expects the company to continue to deliver "strong" margin improvement and sees share buybacks becoming another source of earnings growth as ICUI's leverage ratio declines and management begins to deploy free cash flow.
